The Technical Analyst
First Wave BioPharma, [FWBI]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
First Wave BioPharma, Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-2.07% $2.84
America/New_York / 18 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 5.75 mill |
| EPS: | -47.88 |
| P/E: | -0.0600 |
| Earnings Date: | May 12, 2024 |
| SharesOutstanding: | 2.03 mill |
| Avg Daily Volume: | 0.120 mill |
| RATING 2024-04-18 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Buy | |
| P/E: | Neutral | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.0600 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.01x |
| Company: PE -0.0600 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 2.18 - 3.50 ( +/- 23.35%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-01 | Sapirstein James | Sell | 174 | Common Stock |
| 2024-04-01 | Romano Sarah | Sell | 75 | Common Stock |
| 2024-03-15 | Sapirstein James | Sell | 1 887 | Common Stock |
| 2024-03-15 | Romano Sarah | Sell | 1 120 | Common Stock |
| 2024-03-13 | Syage Jack | Buy | 15 400 | Common Stock, par value $0.0001 per share |
| INSIDER POWER |
|---|
| 93.68 |
| Last 95 transactions |
| Buy: 5 900 618 | Sell: 1 318 677 |
Forecast:
16:00 - $2.82
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $2.82
Forecast 2: 16:00 - $2.82
Forecast 3: 16:00 - $2.82
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $2.84 (-2.07% ) |
| Volume | 0.0381 mill |
| Avg. Vol. | 0.120 mill |
| % of Avg. Vol | 31.82 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For FWBI
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:22 | sell | $5.30 | N/A | Active |
|---|
FWBI
First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties; and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. The company develops FW-COV, which is in Phase II clinical trials for the treatment of severe acute respiratory syndrome coronavirus 2 gastrointestinal infections; FW-UP, which is in Phase II clinical trials for the treatment ulcerative proctitis and ulcerative proctosigmoiditis; FW-ICI-AC for immune checkpoint inhibitor-associated colitis and diarrhea in advanced stage oncology patients; and FW-UC, which is in Phase Ib/IIa clinical trials for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis. It also develops FW-CD, which has completed Phase I clinical trials for Crohn's disease; and adrulipase, an oral, non-systemic, and biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.
Latest Press Releases
2024-04-17 07:00:00 - Press Release
First Wave Biopharma Ceo James Sapirstein To Present At The Planet Microcap Showcase
Boca raton, fla., april 17, 2024 (globe newswire) -- first wave biopharma, inc., (nasdaq: fwbi), (“first wave biopharma” or the “company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (gi) diseases, today announced that james sapirstein, chairman and ceo of first wave biopharma, will present at the planet microcap showcase, which will be held april 30 - may 2, 2024 at the paris hotel & casino in las vegas.
2024-04-15 07:00:00 - Press Release
First Wave Biopharma Ceo James Sapirstein To Participate In 2024 Longwood Healthcare Leaders Conference
Boca raton, fla., april 15, 2024 (globe newswire) -- first wave biopharma, inc., (nasdaq: fwbi), (“first wave biopharma” or the “company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (gi) diseases, today announced that james sapirstein, chairman and ceo of first wave biopharma, will participate in the longwood healthcare leaders conference, which will be held april 29 - may 1, 2024 at the ritz-carlton in key biscayne, florida.
2024-03-18 07:00:00 - Press Release
First Wave Biopharma Announces Two Abstracts On Celiac Disease Research Accepted For Presentation At The 2024 Digestive Disease Week (ddw) Conference
Poster presentations to highlight new quantitative and serologic diagnostic methods for celiac disease detection and determination of intestinal mucosal health
2024-03-14 06:00:00 - Press Release
First Wave Biopharma Announces Completion Of Business Combination With Immunogenx, Adding Phase 3-ready Latiglutenase To Its Late-stage Gi-focused Clinical Pipeline
Latiglutenase is a potentially first-in-class oral biotherapeutic for the treatment of celiac disease james sapirstein, chairman and chief executive officer, to continue leading first wave biopharma; jack syage, ph.d., named president and chief operating officer a strategic u.s. commercial license agreement with a global pharmaceutical company and concurrent institutional investment expected to close in 2h'24 conference call scheduled for today at 8:30 a.m.
2024-03-05 07:00:00 - Press Release
First Wave Biopharma To Participate In ‘fireside Chat' At The 36th Annual Roth Conference
Boca raton, fla., march 05, 2024 (globe newswire) -- first wave biopharma, inc., (nasdaq: fwbi), (“first wave biopharma” or the “company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (gi) diseases, today announced james sapirstein, chairman, president and ceo, will participate in a “fireside chat” with jonathan aschoff, ph.d., managing director and senior research analyst at roth capital partners, during the 36th annual roth conference being held march 17-19, 2024, at the ritz carlton, laguna niguel in dana point, california.
Latest News
2024-04-17 07:00:00 - GlobeNewsWire
First Wave BioPharma CEO James Sapirstein to Present at the Planet MicroCap Showcase
BOCA RATON, Fla., April 17, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chairman and CEO of First Wave BioPharma, will present at the Planet MicroCap Showcase, which will be held April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas.
2024-04-05 10:56:05 - Zacks Investment Research
Here's Why First Wave BioPharma (FWBI) Is a Great 'Buy the Bottom' Stock Now
After losing some value lately, a hammer chart pattern has been formed for First Wave BioPharma (FWBI), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
2024-03-27 13:01:16 - Zacks Investment Research
First Wave BioPharma (FWBI) Upgraded to Buy: What Does It Mean for the Stock?
First Wave BioPharma (FWBI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
2024-03-14 08:05:51 - InvestorPlace
Why Is First Wave BioPharma (FWBI) Stock Up Today?
First Wave BioPharma (NASDAQ: FWBI ) stock is heading higher on Thursday after the clinical-stage biopharmaceutical company completed its business combination with ImmunogenX. First Wave BioPharma used an all-stock transaction to acquire ImmunogenX.
2024-02-13 07:00:00 - GlobeNewsWire
First Wave BioPharma CEO to Present at the BIO CEO & Investor Conference 2024
BOCA RATON, Fla., Feb. 13, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chairman and CEO of First Wave BioPharma, will present at the BIO CEO & Investor Conference, which is planned for February 26-27, 2024, at the Marriott Marquis in New York City.
2024-01-23 07:00:00 - GlobeNewsWire
First Wave BioPharma to Present at the DealFlow MicroCap Conference
BOCA RATON, Fla., Jan. 23, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that it will present at the DealFlow MicroCap Conference, which will be held January 30 – February 1, 2024 at the Caesars Atlantic City Hotel & Casino, in Atlantic City, New Jersey.
2023-12-27 06:37:00 - Market Watch
First Wave BioPharma's stock more than doubles after deal to sell its IBD treatment
Shares of First Wave BioPharma Inc. FWBI, -5.99% rocketed 123% in premarket trading, which puts them on track for a record one-day gain, after the biopharmaceutical company announced an agreement to sell its Niclosamide treatment of inflammatory bowel disease to an “undisclosed biopharmaceutical company.” The stock is currently the biggest gainer among those listed on major U.S. exchanges.
2023-10-03 07:00:00 - GlobeNewsWire
First Wave BioPharma CEO James Sapirstein to Present at the 2023 Roth Healthcare Opportunities Conference
BOCA RATON, Fla., Oct. 03, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chairman, President, and CEO of First Wave BioPharma, will give a presentation at the 2023 Roth Healthcare Opportunities Conference taking place October 12, 2023, in New York City.
2023-09-15 08:45:00 - GlobeNewsWire
First Wave BioPharma To Present at the BIO Investor Forum
BOCA RATON, Fla., Sept. 15, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, President and CEO, will make a company presentation at the BIO Investor Forum being held October 17-18, 2023, at the Hilton San Francisco Union Square in San Francisco.
2023-09-14 07:07:00 - Market Watch
First Wave BioPharma stock soars in active trading after Sanofi license deal
Shares of First Wave BioPharma Inc. FWBI, +8.61% soared 71.7% in active premarket trading Thursday, after the biopharmaceutical company announced an agreement to license Capeserod to Sanofi SNY, -0.73%, which First Wave will repurpose and develop for gastrointestinal indications. Trading volume swelled to 6.5 million shares, already more than double the full-day average of about 2.6 million shares, and enough to make the stock the third-most actively traded in Thursday's premarket.